Tilray | TRLY - Loan Capital


Tilray reported $268.59M in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
Acasti Pharma USD 0 0 Dec/2024
Akebia Therapeutics USD 24.75M 11.64M Jun/2026
Alaunos Therapeutics USD 4.47M 5.85M Jun/2022
Aurora Cannabis CAD 18.13M 15.07M Mar/2026
Avita Medical AUD 42.24M 1.25M Dec/2024
Canopy Growth CAD 217.12M 7.87M Mar/2026
Dianthus Therapeutics USD 0 0 Dec/2024
Divis Laboratories Ltd INR 50M 30M Mar/2026
Ionis Pharmaceuticals USD 1.91B 6.62M Jun/2026
IQVIA Holdings USD 13.7B 284M Jun/2026
Knight Therapeutics CAD 57.78M 26.92M Dec/2025
Moderna USD 597M 6M Jun/2026
Organigram Holdings CAD 60.76M 1.77M Mar/2026
Organon & Co USD 8.55B 75M Mar/2026
Revvity USD 2.63B 1.02M Jun/2026
Tectonic Therapeutic USD 17K 26K Mar/2026
Tilray USD 268.59M 3.82M Sep/2025
Viatris USD 11.61B 801.1M Jun/2026
Xeris Pharmaceuticals USD 188.81M 32.42M Jun/2026
Zealand Pharma A/S 307M 76.14M Mar/2026